Article (Scientific journals)
The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation.
Dahl, Jan-Ulrik; Gray, Michael J; Bazopoulou, Daphne et al.
2017In Nature Microbiology, 2 (4), p. 16267
Peer Reviewed verified by ORBi
 

Files


Full Text
nihms875444.pdf
Author postprint (1.14 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anti-Inflammatory Agents, Non-Steroidal; Polyphosphates; Mesalamine; Animals; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage; Anti-Inflammatory Agents, Non-Steroidal/pharmacology; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; Biofilms/drug effects; Cecum/microbiology; Colitis, Ulcerative/drug therapy; Colitis, Ulcerative/microbiology; Escherichia coli/drug effects; Feces/microbiology; Gastrointestinal Microbiome/drug effects; Gram-Negative Bacteria/drug effects; Gram-Negative Bacteria/genetics; Gram-Negative Bacteria/physiology; Humans; Mesalamine/administration & dosage; Mesalamine/pharmacology; Mesalamine/therapeutic use; Mice; Oxidative Stress/drug effects; Polyphosphates/metabolism; Biofilms; Cecum; Colitis, Ulcerative; Escherichia coli; Feces; Gastrointestinal Microbiome; Gram-Negative Bacteria; Oxidative Stress; Microbiology; Immunology; Applied Microbiology and Biotechnology; Genetics; Microbiology (medical); Cell Biology
Abstract :
[en] Mesalamine serves as the gold standard in treating ulcerative colitis. However, its precise mechanism(s) of action remains unclear. Here, we show that mesalamine treatment rapidly decreases polyphosphate levels in diverse bacteria, including members of the human gut microbiome. This decrease sensitizes bacteria towards oxidative stress, reduces colonization and attenuates persister cell and biofilm formation, suggesting that mesalamine aids in diminishing the capacity of bacteria to persist within chronically inflamed environments.
Disciplines :
Microbiology
Biochemistry, biophysics & molecular biology
Pharmacy, pharmacology & toxicology
Author, co-author :
Dahl, Jan-Ulrik;  Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, USA
Gray, Michael J;  Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, USA
Bazopoulou, Daphne;  Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, USA
Beaufay, François  ;  Université de Liège - ULiège > Département des sciences de la vie > Centre d'Ingénierie des Protéines (CIP) ; Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, USA
Lempart, Justine;  Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, USA
Koenigsknecht, Mark J;  Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, USA
Wang, Ying;  Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, USA
Baker, Jason R;  Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48109, USA
Hasler, William L;  Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48109, USA
Young, Vincent B;  Department of Internal Medicine/Division of Infectious Diseases &Department of Microbiology and Immunology, The University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Sun, Duxin;  Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, USA
Jakob, Ursula;  Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, USA
Language :
English
Title :
The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation.
Publication date :
23 January 2017
Journal title :
Nature Microbiology
eISSN :
2058-5276
Publisher :
Nature Publishing Group, Basingstoke, Hampshire, England
Volume :
2
Issue :
4
Pages :
16267
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
This work was funded by the National Institute of Health grants GM065318 (to U.J.), AI090871 and AI24255 (to V.B.Y.) and by FDA grants HHSF223201000082C and HHSF223201300460A (to D.S.). Clinical samples were collected with help from the Michigan Institute for Clinical & Health Research (MICHR) NIH grant UL1TR000433. J.-U.D. is supported by a postdoctoral fellowship from the Deutsche Forschungsgemeinschaft grant DA1697/1-1.
Available on ORBi :
since 12 January 2026

Statistics


Number of views
7 (2 by ULiège)
Number of downloads
4 (1 by ULiège)

Scopus citations®
 
102
Scopus citations®
without self-citations
81
OpenCitations
 
104
OpenAlex citations
 
123

Bibliography


Similar publications



Contact ORBi